Adjuvant Anti-PD-1 Antibody Therapy for Advanced Melanoma: A Multicentre Study of 78 Japanese Cases.
Adjuvant Anti-PD-1 Antibody Therapy for Advanced Melanoma: A Multicentre Study of 78 Japanese Cases.
复制标题
DOI：
10.2340/actadv.v102.678
复制
发表时间：
2022-08-11
影响因子：
3.6
通讯作者：
中科院分区：
文献类型：
--
作者：
抗PD-1抗体是治疗复发风险较高的黑色素瘤，尤其是BRAF野生型黑色素瘤的最佳辅助治疗方法之一，但抗PD-1抗体在治疗肢端黑色素瘤的辅助治疗中的抗肿瘤效果尚未得到评价。这项研究的目的是分析抗PD-1单抗治疗在包括高比率肢端黑色素瘤的亚洲人群中的疗效和安全性。对78例日本晚期黑色素瘤患者，包括31例(40%)肢端黑色素瘤患者，回顾分析了抗PD-1单抗辅助治疗的疗效和安全性。总的无复发生存率为60.3%(47/78，95%可信区间为49.2-70.4%)，39.7%的患者(31/78，95%可信区间为29.6-50.8%)在PD-1抗体治疗过程中复发。6例(7.9%)因严重不良事件终止治疗。1例(1.3%)因创伤终止治疗。肢端黑色素瘤的无复发存活率为25.8%，高累积日照为60.0%，低累积日照为57.1%。肢端型的12个月无复发生存率显著低于其他皮肤型(p=0.029)。多因素分析显示肢端类型是独立的预后因素(p=0.015)。抗PD-1抗体引起的不良反应发生率为37.1%。这项研究的结果表明，在辅助环境下抗PD-1抗体治疗肢端黑色素瘤的效果不如对其他皮肤类型。
Anti-PD-1 antibodies (Abs) are among the optimal adjuvant therapies for melanoma at high risk of recurrence, especially BRAF wild-type melanoma, but the anti-tumour effects of anti-PD-1 Abs in the adjuvant setting for acral melanoma have not been evaluated previously. The aim of this study was to analyse the efficacy and safety profiles of anti-PD-1 Ab monotherapy in the adjuvant setting in an Asian population including a high ratio of acral melanoma. The efficacy and safety profiles of anti-PD-1 Ab monotherapy in the adjuvant setting were retrospectively analysed in 78 Japanese patients with advanced melanoma, including 31 cases (40%) of acral melanoma. Overall relapse-free survival was 60.3% (47 of 78 cases, 95% confidence interval (CI) 49.2–70.4%), and 39.7% of patients (31 of 78 patients, 95% CI 29.6–50.8%) relapsed during the adjuvant PD-1 Ab treatment. Six cases (7.9%) discontinued the protocol due to serious adverse events. One case (1.3%) discontinued the protocol due to trauma. The relapse-free survival of acral melanoma was 25.8%, whereas that of high cumulative sun damage was 60.0%, and that of low cumulative sun damage was 57.1%. The acral type had a significantly lower 12-month relapse-free survival than other cutaneous types (p = 0.029). The acral type appeared to be an independent prognostic factor on multivariate analysis (p = 0.015). Adverse events due to anti-PD-1 antibody were observed in 37.1% overall. The results of this study suggest that anti-PD-1 Ab therapy in the adjuvant setting is less effective for acral melanoma than for other cutaneous types.
登录
查看更多内容
DOI：
10.1056/nejmoa1504030
发表时间：
2015-07-02
期刊：
The New England journal of medicine
影响因子：
--
作者：
Larkin J;Chiarion-Sileni V;Gonzalez R;Grob JJ;Cowey CL;Lao CD;Schadendorf D;Dummer R;Smylie M;Rutkowski P;Ferrucci PF;Hill A;Wagstaff J;Carlino MS;Haanen JB;Maio M;Marquez-Rodas I;McArthur GA;Ascierto PA;Long GV;Callahan MK;Postow MA;Grossmann K;Sznol M;Dreno B;Bastholt L;Yang A;Rollin LM;Horak C;Hodi FS;Wolchok JD
通讯作者：
Wolchok JD
DOI：
10.1038/modpathol.2017.104
发表时间：
2018-01
期刊：
Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc
影响因子：
--
作者：
Cheng L;Lopez-Beltran A;Massari F;MacLennan GT;Montironi R
通讯作者：
Montironi R
影响因子：
3.4
作者：
Castaneda, C. A.;Torres-Cabala, C.;Abugattas, J.
通讯作者：
Abugattas, J.
影响因子：
50.5
作者：
Nakamura, Y.;Namikawa, K.;Yamazaki, N.
通讯作者：
Yamazaki, N.
影响因子：
5.7
作者：
Iga, Natsuko;Otsuka, Atsushi;Kabashima, Kenji
通讯作者：
Kabashima, Kenji